Osimertinib showed excellent central nervous system (CNS) penetration in preclinical studies as well as in clinical trials, both as first-line and second-line treatments in patients with EGFR-mutant NSCLC [58,69] with no CNS sanctuary. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.